Antibiotic Consumption: Meropenem For meropenem, which was selected as the representative carbapenem agent given its predominant use at this institution—accounting for a mean of 81.0% of total carbapenem prescription requests throughout the study period, followed by imipenem/cilastatin (5.5%) and ertapenem (3.6%) ( Table 2 )—the overall phase comparison did not reach statistical significance ( p = 0.140), largely attributable to seasonal increases in consumption observed between June and November 2025, peaking in November at 76.8 per 1000 patient–days ( Figure 2 ).
← all excerpts
Sustainability and Impact of an Antimicrobial Stewardship Program on Broad-Spectrum Antibiotic Consumption in South Korea: A 14-Month Extended Follow-Up Study
1
0.1400
0.1400